Intracranial meningiomas: II. Diagnosis and treatment.

17:16 EST 23rd November 2014 | BioPortfolio

Summary of "Intracranial meningiomas: II. Diagnosis and treatment."

INTRODUCTION. Meningiomas are the most frequent group of intracranial tumours. In most cases, they are histologically benign tumours, although the fact that they may be located in anatomical areas that are difficult to reach with surgical techniques often means that their treatment must be complemented with oncological therapies. AIMS. To update our current knowledge about the diagnostic techniques and therapeutic options available for intracranial meningiomas, so as to have the latest information on this subject. DEVELOPMENT. The study involves a review of the literature that covers aspects related to the different complementary diagnostic techniques and the alternative methods of treatment. CONCLUSIONS. Magnetic resonance imaging, in all its different sequences, is the preferred diagnostic technique, since it allows 100% intracranial meningiomas to be diagnosed. Although surgery is the preferred treatment technique in most cases, radiotherapy, in its different modes, is an essential therapeutic tool, both as a complement to surgery and as the first choice.

Affiliation

Hospital Clinico de Santiago de Compostela, 15706 Santiago de Compostela, Espana.

Journal Details

This article was published in the following journal.

Name: Revista de neurologia
ISSN: 1576-6578
Pages: 226-32

Links

PubMed Articles [23221 Associated PubMed Articles listed on BioPortfolio]

An Unexpected Lesion in Cerebellopontine Angle: Hemangiopericytoma.

hemangiopericytoma (hPC) is a rare tumor by definition and intracranial hPC makes up to less than one percent of all the intracranial tumors. It is a dural base tumor and its clinical features and rad...

Stereotactic radiosurgery in patients with multiple intracranial meningiomas.

Purpose: Stereotactic radiosurgery (SRS) delivers a potent, highly focused dose of radiation to the tumor while sparing the surrounding normal tissues. The purpose of this study was to assess the outc...

Characterization of pituitary tumor transforming gene in meningiomas.

Pituitary tumor transforming gene (PTTG) is an oncogene and has been detected in several tumors of unrelated histological origin. However, its role in meningiomas is unknown so far. We aim to investig...

Endovascular treatment of intracranial aneurysms: diversity in treatment techniques of varying anatomical presentations.

We discuss and illustrate various endovascular treatment options for intracranial aneurysms, to reflect common technique used in endovascular treatment of brain aneurysm. We select five cases of vario...

Intracranial Hypotension and Hypertension in Children and Adolescents.

The specific aim of this review is to report the features of intracranial pressure changes [spontaneous intracranial hypotension (SIH) and idiopathic intracranial hypertension (IIH)] in children and a...

Clinical Trials [1318 Associated Clinical Trials listed on BioPortfolio]

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa in treating patients with recurrent unresec...

Adult Intracranial Ependymoma

Adult intracranial ependymoma is a relatively rare brain tumour entity, accounting for 2-5% of all intracranial neoplasms. The pertinent prognostic factors as well as the pattern of recurr...

Combination of Hydroxyurea and Verapamil for Refractory Meningiomas

Meningiomas account for 20% of primary adult brain tumors, occurring at an annual incidence of 6 per 100,000 (Louis, Scheithauer et al. 2000). Complete surgical resection is the treatment ...

Monthly SOM230C for Recurrent or Progressive Meningioma

The purpose of this research study is to evaluate the effectiveness and safety of SOM230C in treating recurrent meningiomas. SOM230C is a newly discovered drug that may stop meningioma ce...

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help ...

Medical and Biotech [MESH] Definitions

An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.

Use of reflected ultrasound in the diagnosis of intracranial pathologic processes.

Methods to determine in patients the nature of a disease or disorder at its early stage of progression. Generally, early diagnosis improves PROGNOSIS and TREATMENT OUTCOME.

A well-circumscribed mass composed of tuberculous granulation tissue that may occur in the cerebral hemispheres, cerebellum, brain stem, or perimeningeal spaces. Multiple lesions are quite common. Management of intracranial manifestations vary with lesion site. Intracranial tuberculomas may be associated with SEIZURES, focal neurologic deficits, and INTRACRANIAL HYPERTENSION. Spinal cord tuberculomas may be associated with localized or radicular pain, weakness, sensory loss, and incontinence. Tuberculomas may arise as OPPORTUNISTIC INFECTIONS, but also occur in immunocompetent individuals.

A system for classifying patient care by relating common characteristics such as diagnosis, treatment, and age to an expected consumption of hospital resources and length of stay. Its purpose is to provide a framework for specifying case mix and to reduce hospital costs and reimbursements and it forms the cornerstone of the prospective payment system.

Search BioPortfolio:
Loading